Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
A-Z
> TNF-alpha | Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| TNA-H5228 | Human | Human TNF-alpha Protein, His Tag (active trimer) (MALS verified) |  |   |     |
| TNA-M82E9 | Mouse | Biotinylated Mouse TNF-alpha Protein, His,Avitag™ (active trimer) (MALS verified) |  |    |  |
| TNA-H82E3 | Human | Biotinylated Human TNF-alpha Protein, His,Avitag™ (active trimer) (MALS verified) |  |   |  |
| TNA-H8211 | Human | Biotinylated Human TNF-alpha Protein, epitope tag free, ultra sensitivity (primary amine labeling) (active trimer) (MALS verified) |  |  |  |
| TNA-H4211 | Human | ActiveMax® Human TNF-alpha Protein, Tag Free, low endotoxin (active trimer) (MALS verified) |  |   |   |
Human TNF-alpha, His Tag (active trimer) (MALS verified) (Cat. No. TNA-H5228) induces cytotoxicity effect on the WEH1-13VAR cells in the presence of the metabolic inhibitor actinomycin D. The EC50 for this effect is 0.013-0.074 ng/mL (Routinely tested).
Neutralization assay shows that the cytotoxicity effect of Human TNF-alpha, His Tag (active trimer) (MALS verified) (Cat. No. TNA-H5228) was inhibited by increasing concentration of Adalimumab. The concentration of TNF-alpha used is 1 ng/mL. The IC50 is 26.8 ng/mL (Routinely tested).
Humira (Adalimumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human TNF-alpha, His Tag (active trimer) (MALS verified) (Cat. No. TNA-H5228) with an affinity constant of 0.244 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Humira (Adalimumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind ActiveMax® Human TNF-alpha, Tag Free, low endotoxin (active trimer) (MALS verified) (Cat. No. TNA-H4211) with an affinity constant of 0.255 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Etanercept biosimilar (Hanwha Chemical) | HD-203; MK-8953 | Approved | Hanwha Chemical | Ankylosing Spondylitis (AS), Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | |||||
| Etanercept-szzs | GP-2015 | Approved | Sandoz | ERELZI | fda | Juvenile idiopathic arthritis (JIA), Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | SANDOZ | 2016-08-30 | Juvenile idiopathic arthritis (JIA), Spondyloarthritis, Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | Details |
| Infliximab | TA-650 | Approved | Janssen, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma | REMICADE | fda | Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | CENTOCOR INC | 1998-08-24 | Pediatric ulcerative colitis, Psoriasis vulgaris, Crohn's disease, Mucocutaneous lymph node syndrome (Kawasaki syndrome), Psoriatic erythroderma, Ankylosing Spondylitis (AS), Uveitis, Pustular psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Behcet's disease, Pediatric Crohn's disease | Details |
| Etanercept biosimilar (Nanogen Biopharmaceutical) | Approved | Nanogen Biopharmaceutical Co | Psoriasis, Rheumatoid arthritis (RA) | Details | ||||||
| Adalimumab biosimilar (AXXO) | Approved | AXXO | Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | ||||||
| Etanercept biosimilar (AryoGen Biopharma) | Approved | AryoGen Biopharma | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | ||||||
| Certolizumab pegol | CZP; CDP-870; PHA-738144,CDP870,PHA738144 | Approved | UCB | CIMZIA | fda | Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | UCB INC | 2008-04-22 | Plaque psoriasis, Spondyloarthritis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | Details |
| Etanercept biosimilar (PROBIOMED) | Approved | Probiomed | Rheumatoid arthritis (RA) | Details | ||||||
| Etanercept | TNR-001 | Approved | Amgen, Pfizer, Takeda, Boehringer Ingelheim | ENBREL | fda | Pediatric plaque psoriasis, Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | IMMUNEX | 1998-11-02 | Juvenile idiopathic arthritis (JIA), Pediatric plaque psoriasis, Spondyloarthritis, Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriasis, Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details |
| Adalimumab biosimilar (Zydus Cadila) | Approved | Zydus cadila | Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | ||||||
| Etanercept biosimilar (Shanghai CP Guojian Pharmaceutical) | Approved | Shanghai CP Guojian, Cipla | cfda | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA), Plaque psoriasis | 2015-01-27 | Plaque psoriasis, Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |||
| Etanercept biosimilar (Samsung Bioepis) | SB-4 | Approved | Samsung Bioepis | etanercept | ema | Samsung Bioepis NL B.V. | 2016-01-13 | Juvenile idiopathic arthritis (JIA), Spondyloarthritis, Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (Fujifilm Kyowa Kirin Biologics/Mylan) | FKB-327 | Approved | Fujifilm Kyowa Kirin Biologics, Mylan | adalimumab | ema | Mylan S.A.S. | 2018-09-16 | Plaque psoriasis, Uveitis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriasis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | |
| Adalimumab biosimilar (Biocad) | BCD-057 | Approved | Biocad | Plaque psoriasis | Details | |||||
| Adalimumab biosimilar (Sandoz) | GP-2017 | Approved | Sandoz | adalimumab | ema | Sandoz GmbH | 2018-07-26 | Juvenile idiopathic arthritis (JIA), Uveitis, Spondyloarthritis, Pediatric plaque psoriasis, Ulcerative colitis, Psoriasis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease | Details | |
| Pomalidomide | CC-4047; CDC-394; IMID-4047; IMiD-1 | Approved | Celgene | POMALYST | fda | Multiple myeloma (MM) | CELGENE | 2013-02-08 | Multiple myeloma (MM) | Details |
| Infliximab biosimilar (Bionovis/The Instituto Vital Brazil) | Approved | Bionovis, The Instituto Vital Brazil | Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | Details | ||||||
| Etanercept biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | ||||||
| Etanercept biosimilar (Mochida) | LBEC-0101 | Approved | Mochida, Ayumi | 日本 | Rheumatoid arthritis (RA), Juvenile idiopathic arthritis (JIA) | 持田制药 | 2018-01-19 00:00:00.0 | Juvenile idiopathic arthritis (JIA), Rheumatoid arthritis (RA) | Details | |
| Adalimumab-adbm | BI-695501 | Approved | Boehringer Ingelheim | CYLTEZO | fda | Juvenile idiopathic arthritis (JIA), Ankylosing Spondylitis (AS), Plaque psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | BOEHRINGER INGELHEIM | 2017-08-25 | Juvenile idiopathic arthritis (JIA), Uveitis, Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA) | Details |
| Golimumab | CNTO-148; rTNV148B,CNTO148 | Approved | Janssen, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma | SIMPONI | fda | Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA) | CENTOCOR ORTHO BIOTECH INC | 2009-04-24 | Juvenile idiopathic arthritis (JIA), Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA) | Details |
| Infliximab biosimilar (Amgen) | ABP-710 | Approved | Amgen | AVSOLA | fda | AMGEN INC | 2019-12-06 | Ankylosing Spondylitis (AS), Pediatric ulcerative colitis, Ulcerative colitis, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA), Pediatric Crohn's disease | Details | |
| Infliximab (ABDA) | SB-2 | Approved | Samsung Bioepis, Merck Sharp & Dohme | infliximab | ema | Samsung Bioepis NL B.V. | 2016-05-26 | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease, Pediatric Crohn's disease | Details | |
| Infliximab-qbtx | PF-06438179; PF-6438179; GP-1111,PF06438179; PF6438179 | Approved | Pfizer, Sandoz | IXIFI | fda | PFIZER INC | 2017-12-13 | Psoriatic erythroderma, Ankylosing Spondylitis (AS), Plaque psoriasis, Pustular psoriasis, Ulcerative colitis, Psoriatic arthritis, Psoriasis vulgaris, Crohn's disease, Rheumatoid arthritis (RA), Pediatric Crohn's disease | Details | |
| Pentoxifylline | BL-191; EHT-0201; EHT-201 | Approved | Us Pharm Holdings | TRENTAL | fda | US PHARM HOLDINGS | 1984-08-30 | Peripheral vascular disorders | Details | |
| Infliximab (dyyb) | CT-P13,CTP13 | Approved | Celltrion, Hospira, Nippon Kayaku | infliximab | ema | Pfizer Europe MA EEIG | 2013-09-09 | Psoriatic erythroderma, Plaque psoriasis, Ankylosing Spondylitis (AS), Pustular psoriasis, Psoriasis, Ulcerative colitis, Psoriatic arthritis, Psoriasis vulgaris, Rheumatoid arthritis (RA), Crohn's disease, Pediatric Crohn's disease | Details | |
| Adalimumab biosimilar (Fresenius Kabi) | MSB-11022 | Approved | Merck Serono, Fresenius Kabi | adalimumab | ema | Fresenius Kabi Deutschland GmbH | 2019-04-02 | Uveitis, Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease, Juvenile rheumatoid arthritis (JRA) | Details | |
| Etanercept biosimilar (Hisun-Pfizer Pharmaceuticals) | Approved | Hisun-Pfizer | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | ||||||
| PG-201 | PG-201,PG 201 | Approved | ViroMed, PMG Pharm | Osteoarthritis (OA) | Details | |||||
| Infliximab biosimilar (Nichiiko Pharmaceutical/Aprogen) | GS-071; NI-071 | Approved | Nichi-Iko Pharmaceutical, Aprogen, Zeria, Ayumi | Infliximab biosimilar (Nichiiko Pharmaceutical/Aprogen) | 日本 | Rheumatoid arthritis (RA), Psoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Crohn's disease, Ulcerative colitis | Nichi-Iko Pharmaceutical,Zeria | 2017-09-27 00:00:00.0 | Pustular psoriasis, Ulcerative colitis, Psoriatic arthritis, Psoriasis vulgaris, Crohn's disease, Rheumatoid arthritis (RA) | Details |
| Luminol sodium | MP-1032,MP1032 | Approved | Metrio, Selvim | Psoriasis, Immunological disorders | Details | |||||
| Adalimumab-afzb | PF-06410293 | Approved | Pfizer | ABRILADA | fda | PFIZER INC | 2019-11-15 | Juvenile idiopathic arthritis (JIA), Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (Amgen) | ABP-501 | Approved | Amgen, Daiichi Sankyo | AMJEVITA | fda | Juvenile idiopathic arthritis (JIA), Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA) | AMGEN INC | 2016-09-23 | Juvenile idiopathic arthritis (JIA), Uveitis, Ankylosing Spondylitis (AS), Plaque psoriasis, Ulcerative colitis, Hidradenitis suppurativa, Psoriatic arthritis, Crohn's disease, Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Samsung Bioepis) | SB-5 | Approved | Samsung Bioepis | adalimumab | ema | Samsung Bioepis NL B.V. | 2017-08-24 | Pediatric plaque psoriasis, Spondyloarthritis, Hidradenitis suppurativa, Crohn's disease, Juvenile idiopathic arthritis (JIA), Uveitis, Ankylosing Spondylitis (AS), Psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Pediatric Crohn's disease | Details | |
| Lenalidomide | CDC-501; CC-5013; CDC-5013; ENMD-0997; IMID-5013; IMiD-3 | Approved | Celgene, BeiGene | REVLIMID | fda | Myelodysplastic syndrome (MDS), Mantle cell lymphoma (MCL), Multiple myeloma (MM) | CELGENE | 2005-12-27 | Myelodysplastic syndrome (MDS), Mantle cell lymphoma (MCL), Multiple myeloma (MM), Peripheral T cell lymphoma (PTCL) | Details |
| Adalimumab | D2E7; LU-200134;ABT-D2E7 | Approved | Abbvie | HUMIRA | fda | ABBVIE INC | 2002-12-31 | Spondyloarthritis, Hidradenitis suppurativa, Crohn's disease, Juvenile idiopathic arthritis (JIA), Ankylosing Spondylitis (AS), Plaque psoriasis, Uveitis, Pustular psoriasis, Psoriasis, Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA), Pediatric Crohn's disease | Details | |
| Infliximab biosimilar (Reliance Life Sciences) | BOW-015; R-TPR-015 | Approved | EPIRUS Biopharmaceuticals, Sun Pharmaceutical | Rheumatoid arthritis (RA) | Details | |||||
| Adalimumab biosimilar (Bio-Thera Solutions) | BAT-1406 | Approved | Bio-Thera Solutions | Adalimumab Injection | cfda | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA), Psoriasis | 2019-11-04 | Ankylosing Spondylitis (AS), Psoriasis, Rheumatoid arthritis (RA) | Details | |
| Infliximab biosimilar (AXXO) | Approved | AXXO | Autoimmune diseases, Crohn's disease | Details | ||||||
| Adalimumab biosimilar (Hisun Pharma) | HS-016,HS016 | Approved | Hisun Pharm | Adalimumab Solution for Injection | cfda | Ankylosing Spondylitis (AS) | 2019-12-06 | Plaque psoriasis, Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| Etanercept biosimilar (Amega Biotech) | Approved | Amega Biotech | Rheumatoid arthritis (RA) | Details | ||||||
| Etanercept biosimilar (Mylan) | YLB-113 | Approved | Lupin, Mylan, YL Biologics | etanercept | ema | Mylan IRE Healthcare Limited | 2020-05-20 | Plaque psoriasis, Spondyloarthritis, Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) | Details | |
| Etanercept biosimilar (Mycenax Biotech/TSH Biopharm) | E-11; ENIA-11,E11; ENIA11 | Approved | Mycenax Biotech, TSH Biopharm | Rheumatoid arthritis (RA) | Details | |||||
| Adalimumab biosimilar (Reliance Life Sciences) | R-TPR-021 | Approved | Reliance Life Sciences, Torrent Pharmaceuticals | Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | |||||
| Thalidomide | NSC-527179; NSC-66847; K-17,NSC527179; NSC66847; K17,NSC 527179; NSC 66847; K 17 | Approved | Celgene | THALOMID | fda | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | CELGENE | 1998-07-16 | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | Details |
| Anti-tumour necrosis factor-alpha antibody | Approved | Materia Medica Holding Research and Production Company | Osteoarthritis (OA), Rheumatoid arthritis (RA) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| tgAAC 94 | Phase Ⅱ | Armata Pharmaceuticals | Rheumatoid arthritis (RA), Periodontal disease | Details | |
| Infliximab biobetter (Mabtech/Sorrento) | STI-002 | Phase Ⅲ | Taizhou Mabtech, Sorrento Therapeutics | Rheumatoid arthritis (RA) | Details |
| CMAB815 | CMAB815,CMAB-815; CMAB 815 | IND Filing | Shanghai Biomabs, SinoMab Bioscience Ltd | Rheumatoid arthritis (RA) | Details |
| Human TNF-α monoclonal antibody( Simcere Pharmaceutical) | IND Filing | Nanjing XianSheng Dongyuan Pharmaceutical, Shandong Xiansheng Medejin Bio-pharmaceutical, Simcere | Unspecified | Details | |
| Recombinant anti-TNFα monoclonal antibody (Wuhan Institute of Biological Products) | Phase Ⅰ | Wuhan Institute of Biological Products | Plaque psoriasis, Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| Recombinant anti-TNFα antibody (Shanghai Xiesheng Medicine) | Phase Ⅰ | Shanghai Xiesheng Pharmaceutical Technology | Unspecified | Details | |
| Adalimumab biosimilar (Shanghai Maitaiyabo Biotech) | IND Filing | Shanghai Maitai Yabo Biological Technology | Rheumatoid arthritis (RA) | Details | |
| Hemay007 | Hemay-007 | Phase Ⅱ | Tianjin Hemay Biotech | Ulcerative colitis | Details |
| BLX-1002 | BLX-1002 | Phase Ⅱ | Orchid | Type 2 diabetes | Details |
| Azacitidine/Lenalidomide | Phase Ⅱ | Celgene | Acute myeloid Leukemia (AML) | Details | |
| Adalimumab biosimilar (Bionovis/The Instituto Vital Brazil) | Phase Not Specified | Bionovis, The Instituto Vital Brazil | Plaque psoriasis, Ankylosing Spondylitis (AS), Ulcerative colitis, Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease | Details | |
| EYS-606 | EYS-606 | Phase Ⅱ | Eyevensys | Uveitis | Details |
| Infliximab biosimilar (Shanghai CP Guojian) | Phase Ⅲ | Shanghai CP Guojian | Rheumatoid arthritis (RA) | Details | |
| HMPL-004 (Hutchison Medipharma) | HMPL-004 | Phase Ⅲ | Hutchison Medipharma | Ulcerative colitis, Crohn's disease | Details |
| Recombinant anti-TNFα antibody (Sailemin Biotech) | IND Filing | Hainan Sailemin Biological Technology | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| REN-1654 | CPI-1189; REN-1189; REN-1654,REN1654,REN1189,CPI1189 | Phase Ⅱ | Evotec | Postherpetic neuralgia (PHN), Sciatica | Details |
| Adalimumab biosimilar (LG Life Sciences) | LBAL | Phase Ⅲ | LG Chem, Mochida | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Beijing Luzhu Biotechnology) | Phase Ⅰ | Beijing Luzhu Biotechnology | Rheumatoid arthritis (RA) | Details | |
| ONO-4007 | ONO-4007 | Phase Ⅱ | Ono Pharmaceutical | Cancer chemotherapy | Details |
| Recombinant human anti-TNFα monoclonal antibody (Taizhou Mabtech) | IND Filing | Taizhou Mabtech | Unspecified | Details | |
| PUR-0110 | PUR-0110; PCT-233 | Phase Ⅲ | PurGenesis Technologies | Radiodermatitis | Details |
| ISIS-104838 | ISIS 104838 | Phase Ⅱ | Ionis | Psoriasis, Rheumatoid arthritis (RA) | Details |
| CC-10015 | CC-10015 | Phase Ⅱ | Celgene | Sarcoidosis | Details |
| LP-0058 | LP-0058; LEO-32731,LP0058,LEO32731 | Phase Ⅱ | Leo Pharma | Psoriasis, Atopic dermatitis | Details |
| GSK-2800528 | GSK-2800528,GSK 2800528,GSK2800528 | Phase Ⅰ | GlaxoSmithKline | Psoriasis, Inflammation | Details |
| Adalimumab biosimilar (Oncobiologics) | ONS-3010 | Phase Ⅲ | Outlook Therapeutics | Plaque psoriasis | Details |
| Adalimumab biosimilar (CTTQ Pharma) | BLA Filing | Chiatai Tianqing (CTTQ) | Rheumatoid arthritis (RA) | Details | |
| QR-449 | QR-440; QR-443; QR-449 | Phase Ⅰ | ProPhase Labs | Cachexia, Metabolic disorders, Pain | Details |
| Infliximab biosimilar (Shanghai Biomabs) | CMAB-008 | BLA Filing | Shanghai Biomabs | Rheumatoid arthritis (RA) | Details |
| HP-228 | HP-228; ILP-228 | Phase Ⅱ | Sygnis | Obesity, Type 2 diabetes, Postoperative pain, Inflammation | Details |
| Adalimumab biosimilar (Coherus BioSciences) | CHS-1420 | Phase Ⅲ | Coherus Biosciences | Plaque psoriasis | Details |
| Adalimumab biosimilar (CinnaGen) | Phase Ⅲ | CinnaGen | Rheumatoid arthritis (RA) | Details | |
| Infliximab biosimilar (Biocad) | BCD-055 | Phase Ⅲ | Biocad | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details |
| Infliximab biosimilar (Genor Biopharma) | GB-242,GB242 | Phase Ⅲ | Genor Biopharma | Rheumatoid arthritis (RA) | Details |
| CDP-571 | CDP-571; BAY-10-3356; cb-0010,CDP 571; BAY 10 3356; cb 0010,CDP571; BAY103356; cb0010 | Phase Ⅲ | Celltech, Biogen | Type 2 diabetes, Septic shock, Rheumatoid arthritis (RA), Crohn's disease | Details |
| Recombinant anti-TNFα monoclonal antibody (Livzon Group) | AT-132; LZM-001 | Phase Ⅱ | Livzon Group Livzon Pharmaceutical Factory | Rheumatoid arthritis (RA) | Details |
| Placulumab | ART-621; CEP-37247; PN-0621; Dom-0200 | Phase Ⅱ | Peptech UK, Domantis, Arana, Teva | Psoriasis, Inflammation, Rheumatoid arthritis (RA), Sciatica | Details |
| Recombinant human TNF-α monoclonal antibody (Sinocelltech) | SCT-630 | Phase Ⅲ | Sinocelltech | Plaque psoriasis | Details |
| AZD-9773 (BTG) | Phase Ⅱ | BTG plc, AstraZeneca | Septic shock, Sepsis | Details | |
| JNJ-63823539 | JNJ-63823539 | Phase Ⅰ | Janssen | Rheumatoid arthritis (RA) | Details |
| MM-A01-01 | MM-A01-01,MMA0101 | Phase Ⅱ | Myungmoon Pharm | Rheumatoid arthritis (RA) | Details |
| Etanercept biosimilar (Bionovis/The Instituto Vital Brazil) | Phase Not Specified | Bionovis, The Instituto Vital Brazil | Plaque psoriasis, Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | Details | |
| Hemay-005 | Hemay-005 | Phase Ⅱ | Tianjin Hemay Biotech, Hainan Hailing Chemipharma Corporation Limited | Ankylosing Spondylitis (AS), Plaque psoriasis, Psoriatic arthritis, Behcet's disease | Details |
| Adalimumab biosimilar (Alphamab) | KN-002 | Phase Ⅰ | Alphamab | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Genor Biopharma) | BCD-100; GB-232 | Phase Ⅰ | Genor Biopharma, Biocad | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Danhong Pharma) | BC-002 | Phase Ⅰ | Danhong Pharma | Plaque psoriasis, Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details |
| NPH-30907 | NPH-30907 | Phase Ⅱ | Piramal Phytocare | Fungal infection | Details |
| Adalimumab biosimilar (Tonghua Dongbao Pharmaceutical) | Phase Ⅲ | Tonghua Dongbao Pharmaceutical | Plaque psoriasis | Details | |
| Adalimumab biosimilar (Shanghai Henlius Biotech) | HLX-03 | BLA Filing | Shanghai Henlius Biotech | Plaque psoriasis, Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Mylan/Biocon) | BMO-2; MYL-1401-A | BLA Filing | Biocon, Mylan | Psoriasis, Rheumatoid arthritis (RA) | Details |
| INDUS-83030 | INDUS-83030 | Phase Not Specified | Indus Biotech Private Limited | Rheumatoid arthritis (RA) | Details |
| AMG-548 | AMG-548 | Phase Ⅰ | Amgen | Rheumatoid arthritis (RA), Arthritis | Details |
| Recombinant human anti-TNFα monoclonal antibody (Qilu Pharmaceutical) | Phase Ⅰ | Qilu Pharmaceutical | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| Etanercept biosimilar (Zenotech Laboratories) | Phase Not Specified | Zenotech laboratories | Rheumatoid arthritis (RA) | Details | |
| Adalimumab biosimilar (HEC Pharma) | IND Filing | HEC Pharm | Rheumatoid arthritis (RA) | Details | |
| Recombinant chimeric anti-TNFα antibody (Hisun Pharma) | HS-626 | BLA Filing | Hisun Pharm | Plaque psoriasis | Details |
| ABT-122 | ABT-122; D2E7-GS10-B6-17 | Phase Ⅱ | Abbvie | Rheumatic disorders, Psoriatic arthritis | Details |
| Tumour necrosis factor alpha kinoid | TNF-K; TNF-K005 | Phase Ⅱ | Neovacs | Rheumatoid arthritis (RA), Crohn's disease | Details |
| Etanercept biosimilar (Clover Biopharmaceuticals) | SCB-808 | Phase Ⅲ | Clover Biopharmaceuticals | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details |
| Etanercept biosimilar (Qilu Pharmaceutical) | QL-0902 | BLA Filing | Qilu Pharmaceutical | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details |
| IBPM005IX (Inbiopro Solutions) | Phase Not Specified | Inbiopro Solutions | Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA), Crohn's disease, Juvenile rheumatoid arthritis (JRA) | Details | |
| Etanercept biosimilar (AvesthaGen) | Phase Ⅲ | Avesthagen | Rheumatoid arthritis (RA) | Details | |
| K-832 | K-832 | Phase Ⅱ | Kowa | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Momenta Pharmaceuticals) | BAX-2923; M-923; BAX-923 | Phase Ⅲ | Momenta, Shire | Plaque psoriasis, Autoimmune diseases, Inflammation, Rheumatoid arthritis (RA) | Details |
| AN-0128 | AN-0128; CRM-0005; ONT-0001,AN0128,ONT0001,CRM0005 | Phase Ⅱ | Anacor Pharmaceuticals | Atopic dermatitis | Details |
| V-565 | V-565 | Phase Ⅱ | VHSquared | Crohn's disease | Details |
| Etanercept biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) | BLA Filing | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Rheumatoid arthritis (RA) | Details | |
| Anti-tumour necrosis factor alpha (Livzon) | Phase Ⅰ | Livzon Group | Autoimmune diseases | Details | |
| Adalimumab with ENHANZE technology (Abbvie) | Phase Ⅰ | Abbvie | Unspecified | Details | |
| Recombinant human anti-TNFα monoclonal antibody (Weimingdamu Biotech) | Phase Ⅰ | Anhui Sinobioway Damu Biomedicine | Rheumatoid arthritis (RA) | Details | |
| AME-527 | AME-527 | Phase Ⅱ | Applied Molecular Evolution | Rheumatoid arthritis (RA) | Details |
| YS-IL6 | YS-IL6; YSIL-6; YSIL6-O-RA; YSIL6-T-PS | Phase Ⅱ | Y's Therapeutics | Rheumatoid arthritis (RA) | Details |
| OCT-B201 | OCT-B201; BT-201 | Phase Ⅰ | Oscotec | Osteoarthritis (OA) | Details |
| Certolizumab (Intrexon) | AG-014 | Phase Ⅰ | Intrexon Corporation | Inflammatory bowel disease | Details |
| DLX-105 | DLX-105; ESBA-105 | Phase Ⅱ | ESBATech, Cell Medica | Uveitis, Plaque psoriasis, Crohn's disease, Dry eye disease | Details |
| Etanercept biosimilar (Biotrion) | BT-D001 | Phase Ⅲ | Biotrion | Rheumatoid arthritis (RA) | Details |
| Etanercept biosimilar (Shanghai Celgen) | Phase Ⅲ | Shanghai Celgen Bio | Plaque psoriasis | Details | |
| Adalimumab biosimilar (Innovent Biologics) | IBI-303 | BLA Filing | Innovent Biologics | Ankylosing Spondylitis (AS) | Details |
| AVX-470 | AVX-1350; AVX-470; AVX-470h | Phase Ⅰ | Avaxia Biologics | Ulcerative colitis | Details |
| COVA-322 | COVA-322 | Phase Ⅱ | Covagen | Plaque psoriasis | Details |
| CYT 007 TNFQb | Phase Ⅱ | Cytos | Psoriasis, Rheumatoid arthritis (RA) | Details | |
| MNX-160 | LMP-160; MNX-160 | Preclinical | Nonindustrial source, Macronex | Cachexia, Diabetes, Psoriasis, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Asthma, Adult respiratory distress syndrome (ADRS) | Details |
| KOB-03 | KOB-03 | Phase Ⅱ | Dong Wha Pharmaceuticals | Allergic rhinitis (AR) | Details |
| Adalimumab biosimilar (Alvotech) | AVT-02 (Alvotech) | Phase Ⅲ | Alvotech | Plaque psoriasis, Autoimmune diseases | Details |
| BIRB-1017 | BIRB-1017 | Phase Not Specified | Boehringer Ingelheim | Psoriasis, Rheumatoid arthritis (RA) | Details |
| Etanercept (Neurokine Pharmaceuticals) | NK-001; NP-1 | Phase Not Specified | Pivot Pharmaceuticals | Cognitive disorders | Details |
| ENMD-0995 | S-3APG; ENMD-0995 | Phase Ⅰ | Celgene, Boston Children's Hospital | Multiple myeloma (MM) | Details |
| PMI-001 | PMI-001,PMI 001,PMI001 | Phase Ⅲ | Phytomedics | Lupus vulgaris, Psoriasis, Multiple sclerosis (MS), Rheumatoid arthritis (RA) | Details |
| Recombinant anti-TNFα human monoclonal antibody (Jilin Kanghui Biotech) | IND Filing | Jilin Kanghui Biological Technology | Unspecified | Details | |
| Adalimumab biosimilar (Hualan Biological Engineering) | Phase Ⅲ | Hualan Biological Engineering | Rheumatoid arthritis (RA) | Details | |
| Golimumab biosimilar (Bio-thera) | BAT-2506 | Phase Ⅰ | Bio-Thera Solutions | Ankylosing Spondylitis (AS), Psoriatic arthritis, Rheumatoid arthritis (RA) | Details |
| Ozoralizumab | ATN-103; PF-05230896; PF-5230896; TS-152 | Phase Ⅲ | Ablynx, Eddingpharm, Pfizer, Taisho Pharmaceutical | Rheumatoid arthritis (RA) | Details |
| DOM-0215 | DOM-0215,Dom 0215,Dom0215 | Preclinical | GlaxoSmithKline | Rheumatoid arthritis (RA) | Details |
| Human anti-TNFα monoclonal antibody (DZM Biotech) | Phase Ⅰ | DZM Biotech | Rheumatoid arthritis (RA) | Details | |
| YHB-1411-2 | YHB-1411-2; YHB1411-2; YHB-14112; MAb YHB1411-2 | Phase Ⅰ | Yuhan Corporation | Rheumatoid arthritis (RA) | Details |
| LY-3114062 | LY-3114062; LY3114062 | Phase Ⅰ | Lilly | Arthritis | Details |
| Recombinant human monoclonal antibody specific for human tumor necrosis factor (North China Pharmaceutical) | Phase Ⅰ | North China Pharmaceutical | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| ABBV-257 | ABBV-257; DVD-1; DVD-Ig-1 | Phase Ⅰ | Abbott | Rheumatoid arthritis (RA) | Details |
| NV-52 | NV-52; NV-07β | Phase Ⅱ | Novogen | Ulcerative colitis, Crohn's disease, Inflammatory bowel disease | Details |
| Lenercept | TNFR55-Ig1; RO-452081; p55TNFR-Ig; NFR55-IgG1 | Phase Ⅲ | Roche | Septic shock, Rheumatoid arthritis (RA) | Details |
| PF-5230905 | ATN-192;PF-05230905; PF-5230905 | Phase Ⅰ | Ablynx | Rheumatoid arthritis (RA) | Details |
| Tanfanercept | HBM-9036; HL-036 | Phase Ⅲ | HanAll, Harbour BioMed, Daewoong | Dry eye disease | Details |
| Adalimumab biosimilar (Jiangsu Zhonghe) | UBP-1211,UBP1211; UBP 1211 | Phase Ⅲ | Jiangsu Zhonghe Medicine, Shanghai Junshi Biosciences | Rheumatoid arthritis (RA) | Details |
| Adalimumab biosimilar (Celltrion) | CT-P17 | Phase Ⅲ | Celltrion | Rheumatoid arthritis (RA) | Details |
| Anti-TNFalpha polyclonal antibody (Verigen) | Phase Ⅱ | Genzyme, Italchimici | Crohn's disease, Rheumatoid arthritis (RA) | Details | |
| Etanercept biosimilar (Coherus Biosciences) | BAX-2200; CHS-0214 | Phase Ⅲ | Coherus Biosciences, Daiichi Sankyo | Plaque psoriasis, Rheumatoid arthritis (RA) | Details |
| SA-13353 | DE-096; SA-13353,DE096,SA13353 | Phase Ⅱ | Santen, Ayumi | Rheumatoid arthritis (RA), Diabetic macular edema | Details |
| Adalimumab biosimilar (Dong-A ST/Meiji Seika Pharma) | DA-3113; DMB-3113 | Phase Ⅰ | Dong-A Pharmaceutical, Meiji Seika Pharma | Rheumatoid arthritis (RA) | Details |
| Ro-327315 | Ro-327315; Ro-32-7315 | Phase Ⅰ | Roche | Rheumatoid arthritis (RA) | Details |
| Recombinant mutant human tumor necrosis factor alpha (State Key Laboratory of Cancer Biology) | Phase Ⅱ | State Key Laboratory of Cancer Biology | Gastric cancer, Colorectal cancer, Lung cancer, Renal carcinoma, Head and neck cancer | Details | |
| Recombinant humanized anti-TNFα monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | IND Filing | Shenzhen Main Luck Pharmaceuticals | Ankylosing Spondylitis (AS), Rheumatoid arthritis (RA) | Details | |
| ABX-0401 | ABX-0401 | Phase Ⅱ | Sanofi, Pfizer | Immune-inflammatory diseases, Rheumatoid arthritis (RA), Inflammatory bowel disease | Details |
| Adalimumab biosimilar (Prestige BioPharma) | PBP-1502 | Phase Ⅰ | Prestige BioPharma, Huons | Arthritis | Details |
| Adalimumab biosimilar (Hetero Drugs) | Phase Ⅲ | Hetero Drugs | Rheumatoid arthritis (RA) | Details | |
| BB-2275 | BB-2275 | Preclinical | Vernalis | Cachexia, AIDS related cachexia, Cancer related cachexia | Details |
| Recombinant human TNF-α monoclonal antibody(SL Pharma/Combio) | KM113 | IND Filing | Beijing ShuangLu Pharmaceutical, Combio | Autoimmune diseases | Details |
| Genz-29155 | Genz-29155 | Phase Ⅰ | Sanofi | Transplant rejection, Multiple sclerosis (MS) | Details |
| Doramapimod | BIBR-796; BIRB-0796; BIRB-796; BIRB-796-BS,BIBR796,BIRB0796,BIRB796 BS | Phase Ⅲ | Boehringer Ingelheim | Psoriasis | Details |
| Adalimumab biosimilar (Synermore Biologics) | SYN-060 | IND Filing | Synermore Biologics, Lonn Ryonn Pharma | Rheumatoid arthritis (RA) | Details |
| OCS-02 | OCS-02 | Phase Ⅱ | Oculis Pharma, Novartis | Dry eye disease | Details |
| Adalimumab biosimilar (Eastern Biotech) | JY-026,JY026 | Phase Ⅰ | Eastern Biotech | Juvenile idiopathic arthritis (JIA), Plaque psoriasis, Ankylosing Spondylitis (AS), Crohn's disease, Rheumatoid arthritis (RA) | Details |
| BCD-121 | BCD-121 | Phase Ⅰ | Biocad | Rheumatoid arthritis (RA) | Details |
| Golnerminogene pradenovec | ADgvEGR.TNF.11D | Phase Ⅲ | Asahi Kasei, GenVec, National Cancer Institute | Pancreatic cancer | Details |
| Acetylcysteine/Pentoxifylline | PTL-202 | Phase Ⅰ | Pacific Therapeutics, IntelGenx Corp, RA Chem Pharma | Idiopathic pulmonary fibrosis (IPF) | Details |
| Fluorofenidone | AKF-PD,AKFPD | Phase Ⅰ | Central South University, Dierepharma, Hainan Haiyao Pharma | Hepatic fibrosis, Renal fibrosis | Details |
| Wogonin | Phase Ⅰ | Daewoong, China Pharmaceutical University, Hefei Cosource Medicine Technology, Buchang Pharma | Gastric cancer, Leukemia, Liver cancer | Details |
This web search service is supported by Google Inc.
